Abstract : Purpose : To report the efficacy of intravitreal injections of bevacizumab for diabetic macular edema (DME) in the short-term. Design : Retrospective, noncomparative, interventional case series. Methods : Medical records of 20 eyes of 19 patients who underwent intravitreal injections of bevacizumab for persistent diabetic macular edema were reviewed retrospectively. All eyes received intravitreal injections of bevacizumab (1.25 mg/ 0.05 ml). The clinical course of best-corrected visual acuity (BCVA) using a logarithm of the minimum angle of resolution chart, and averaged foveal retinal thickness using an optical coherence tomography (OCT) were monitored for up to four weeks after the injection. Results : BCVA at one week improved by two lines or more in six eyes (30% %) and in nine eyes (45% %) at four weeks. However, no significant improvement in the mean BCVA from baseline was observed at one week (P 0.05) and four weeks (P 0.05). Mean retinal thicknesses (RT) were 411 170 !m at baseline, 349 102 !m at one week after the injection (P 0.05), and 380 159 !m at four weeks (P 0.05). One week after the injection, significant regression of macular edema was seen. However, recurrence occurred at four weeks. No complications such as severe vision loss, endophthalmitis, or systemic events developed. Conclusion : No changes in BCVA and RT were observed in the short-term observation after the intravitreal injection of bevacizumab for DME.
INTRODUCTION
Diabetic retinopathy (DR) is a major cause of visual loss in patients with diabetes mellitus. Diabetic macular edema (DME), which can occur at any stage of DR, is characterised by increased vascular permeability and the deposition of hard exudates at the central retina. Diabetic macular edema is now the principal cause of vision loss in people with diabetes (1) .
Bevacizumab (Avastin TM , Genentech Inc. San Francisco, California, USA) is a full length humanized antibody that binds to all subtypes of vascular endothelial growth factor (VEGF) and has been approved by the US Food and Drug Administration for the treatment of metastatic colorectal cancer (2) . Recent reports have suggested that bevacizumab may be useful for the treatment of choroidal neovascularization (CNV), diabetic macular edema, DR and macular edema associated with retinal venous occlusive diseases (3) (4) (5) .
The purpose of this study was to report the efficacy of intravitreal injections of bevacizumab by measuring visual acuity (VA) and foveal retinal TM   ) for shortterm treatment of diabetic macular edema thickness (RT) after intravitreal injection of bevacizumab for DME.
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METHODS
We retrospectively reviewed 20 eyes of 19 consecutive Japanese patients (12 males, 7 females) with DME treated with intravitreally administered bevacizumab. The patients were followed for four weeks at Tokushima University Hospital. The Ethical Committee of the University of Tokushima approved the off-label use of bevacizumab. The decision to treat with intravitreally administered bevacizumab was made by the patient after a complete discussion on its risks, benefits and alternative treatments. If the patient decided to proceed with bevacizumab therapy, they signed a consent form before administration.
The eye was prepared with a topical anesthetic and a drop of antibiotic before the injection. The eyelid margin was prepared with a povidone/iodine solution. A wire speculum was placed followed by several drops of diluted povidone/iodine solution to the conjunctiva at the injection site. An injection of 1.25 mg of bevacizumab (0.05 ml of bevacizumab at a concentration of 25 mg/ml) was administered using a 30 gauge needle from the pars plana.
Patients were examined at baseline, at one week, two weeks, and four weeks. We recorded the BCVA measured with a Japanese standard decimal VA chart and calculated the mean BCVA using the logarithm of the minimum angle of resolution (logMAR) scale, intraocular pressure (IOP), and fluorescein angiography (FA). Analysis of retinal anatomic features was performed using an optical coherence tomography (OCT, Stratus III OCT ; Carl Zeiss, Dublin, California, USA). The RT at the fovea of the 1-mm central retina was determined using six low-resolution diagonally oriented fast macula scans.
Statistical analysis was performed using the Student's t-test to compare the VA, IOP and the central RT at one, two, and four weeks from baseline.
RESULTS
Twenty eyes of 19 patients (12 males, 7 females) with DME were studied. The ages of the patients ranged from 44 to 76 years with a mean of 59.7! 8.0 years. All patients had type II diabetes. There was no history of any other ocular disease except for refractive errors or cataracts. All patients had panretinal photocoagulation. Three patients had subTenon's capsule injection of 20 mg triamcinolone acetonide (TA). Nine patients had cataract surgery with intraocular lens implantation, and nine patients had vitrectomy. The glycosylated hemoglobin (HbA1c) averaged 7.1!1.1 before starting the study ( Table 1) .
The BCVA at one week improved by two lines or more in six eyes (30%) (Figure 1 ) and the BCVA at Glycosylated hemoglobin (HbA1C, %), Mean!SD 7.1!1.1
Panretinal photocoagulation 20
Macula focal/grid laser treatment 0
Prior sub tenon triamcinolone injection 3
Prior pars plana vitrectomy 9
Lens status, no Changes in the best-corrected visual acuity (BCVA) at one week after treatment. Six eyes (30%) improved by two lines or more, one eye (5%) decreased by two lines or more. There is no significant improvement between the mean BCVA and baseline (P!0.05, paired t-test).
four weeks improved in nine eyes (45%) (Figure 2 ). No significant improvement in the mean BCVA from baseline was observed at one week (P"0.05), or four weeks (P"0.05).
Mean RT was 411!170 μm at baseline, 349!102 μm at one week, 365!149 μm at two weeks, and 380!159 μm at four weeks ( Figure 3) . The central RT significantly decreased from baseline at one week (P!0.05). However, no significant decrease was recognized at two weeks (P"0.05), and four weeks (P"0.05). At the four weeks follow-up visit, FA showed resolution of leakage in some eyes.
During the follow-up of the patients in this study, no complications such as inflammation, increased IOP (Figure 4) , severe vision loss, endophthalmitis, or systemic events were observed. DISCUSSION DME has been characterized by inflammation, including intravitreous induction of proinflammatory cytokines (6) , intraretinal expression of proinflammatory caspases (7) and mediators. Many clinical investigators have found that an intravitreal injection of TA may reduce macular edema. However, the use of intravitreal TA may lead to complications such as increased IOP, progression of cataract and endophthalmitis (8) .
Bevacizumab is an anti-VEGF agent that is approved for the treatment of disseminated colorectal cancer but is not licensed for intraocular use. However, bevacizumab appears to show a similar efficacy for the treatment of DME and proliferative DR (9) .
VEGF has been shown to be an endothelial cellspecific mitogen and an angiogenic inducer. It is also a vascular permeability factor ; it has been demonstrated to increase the permeability of retinal vessels by increasing the phosphorylation of tight junction proteins (10) . It was found that the concentration of VEGF in the vitreous increased and correlated with the severity of macular edema in patients with DME (11), therefore anti-VEGF therapy is expected to show a dramatic reduction of DME. Bevacizumab has attracted interest because of its low cost ; however systemic safety is not approved (12, 13) .
We conformed to the widely used concentration of the drug (1.25 mg bevacizumab) in this study. Anti-VEGF therapy of the intravitreally administered bevacizumab showed a marked reduction of macular edema soon after the injection at one week. However, recurrence of macular edema occurred within four weeks. A retinal penetration study revealed the absence of bevacizumab four weeks after the injection (14) , which may suggest the limited effect of bevacizumab on suppression of VEGF activity.
Mean retinal thickness was reduced at one week after the injection (P!0.05). However, no significant improvement in the mean BCVA. It is possible that visual acuity may not improve with the same time course as thickness of the macula. It depends on macular function improvement and it may have timelag (15) .
Maia, et al. reported that a combination therapy of intravitreal triamcinolone and laser photocoagulation decreased DME (16) . Recently, a combination therapy with intravitreal bevacizumab and photodynamic therapy (PDT) for CNV in patients with AMD has been reported to improve VA and anatomic changes and reduce retreatment rates (17) . Therefore, we think that the combination of laser photocoagulation with intravitreal bevacizumab may improve BCVA and decrease RT more than laser photocoagulation alone or intravitreal bevacizumab alone for the treatment of moderate DME.
In summary, the therapy of intravitreal bevacizumab alone for DME is effective in the short-term, however it is not effective in the long-term.
